Program
zuberitamab
Also written as “Zuberitamab 1000mg”, “HS006+CHOP” and “Zuberitamab 600mg”.
Its studies are mostly in Glomerulonephritis, Membranous · Lymphoma, Large B-Cell, Diffuse, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| BioRay Pharmaceutical | 22 open or running | phase 3since Sep 15, 2026 | Oct 13, 2024 | Mar 31, 2027phase 2 · NCT06642909 |
| Zhejiang Hisun Pharmaceutical | 10 open or running | phase 2since Mar 26, 2018 | Mar 26, 2018 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 26, 2018First study: phase 2 study in Lymphoma, Large B-Cell, DiffuseNew to Zhejiang Hisun PharmaceuticalZhejiang Hisun Pharmaceutical · NCT03485118 · 137 enrolled
- Oct 13, 2024BioRay Pharmaceutical's first study: phase 2 study in Primary Membranous NephropathyNew to BioRay PharmaceuticalBioRay Pharmaceutical · NCT06642909 · 135 enrolled · China
- Sep 15, 2026Phase 3 study in Primary Membranous NephropathyPhase 3 reachedBioRay Pharmaceutical · NCT07830433 · 150 planned · China
Ahead
- Mar 31, 2027Primary completion: phase 2 study in Primary Membranous NephropathyBioRay Pharmaceutical · NCT06642909
- Dec 2029Primary completion: phase 3 study in Primary Membranous NephropathyBioRay Pharmaceutical · NCT07830433
TargetBeta
“A recombinant human-mouse chimeric monoclonal antibody directed against the human B-cell-specific cell surface antigen CD20, ”NCIt, by rule
“B-lymphocyte antigen CD20 binding agent”ChEMBL 37, by rule
Other programs on MS4A1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Rituximabrule | Hoffmann-La Roche | phase 4 | 175 |
| ocrelizumabrule | Hoffmann-La Roche | phase 4 | 42 |
| obinutuzumabrule | Hoffmann-La Roche | phase 4 | 42 |
| ublituximabrule | TG Therapeutics | phase 3 | 23 |
| mosunetuzumabrule | Hoffmann-La Roche | phase 3 | 14 |
| glofitamabrule | Hoffmann-La Roche | phase 3 | 13 |
| epcoritamabrule | Genmab | phase 3 | 13 |
| Anti-CD20 Monoclonal Antibody MIL62rule | beijing-mabworks-biotech-co-ltd | phase 3 | 10 |
| odronextamabrule | Regeneron Pharmaceuticals | phase 3 | 8 |
| TQB2825 | Sino Biopharmaceutical | phase 3 | 5 |
| rondecabtagene autoleucelrule | lyell-immunopharma-inc | phase 3 | 2 |
| zamtocabtagene autoleucelrule | miltenyi-biomedicine-gmbh | phase 2 | 8 |
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07830433Primary Membranous Nephropathy · China | 3 | Not yet recruiting | BioRay Pharmaceutical | Dec 2029 | 150 |
| NCT06642909Primary Membranous Nephropathy · China | 2 | Active, not recruiting | BioRay Pharmaceutical | Mar 31, 2027 | 135 |
| NCT03485118Lymphoma, Large B-Cell, Diffuse | 2 | Completed | Zhejiang Hisun Pharmaceutical | Aug 12, 2016 | 137 |
How it is read
Names in the registry
- “Zuberitamab 1000mg”, 2 entries
- “HS006+CHOP”, 2 entries
- “Zuberitamab 600mg”, 1 entry
Conditions, from the studies’ own filings
- Glomerulonephritis, Membranous, 2 studies
- Lymphoma, Large B-Cell, Diffuse, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.